Maxim Group Downgrades Tekmira Pharmaceuticals To Hold

Analysts at Maxim Group downgraded

from Buy to Hold. The price target for Tekmira Pharmaceuticals has been lowered from $27.00 to $14.00. Tekmira Pharmaceuticals shares have gained 10.51 percent over the past 52 weeks, while the S&P 500 index has surged 7.33 percent in the same period. Tekmira Pharmaceuticals' shares closed at $14.93 yesterday.